Industry Overview - The weight-loss market is one of the most active therapeutic areas in the pharmaceutical industry and is projected to continue growing significantly in the foreseeable future [1] Novo Nordisk - Novo Nordisk is a leader in the weight loss market with its GLP-1 drug, Wegovy, which is among the best-selling medicines in this niche [3] - The company has launched an oral version of Wegovy and has several promising pipeline candidates, including CagriSema, which has outperformed Wegovy in clinical studies and is under consideration for approval [3] - Novo Nordisk's market cap is $130 billion, with a current price of $38.58 and a gross margin of 80.90% [4][5] - The company is expanding its portfolio with candidates like amycretin, currently in phase 3 studies, and UBT251, which has shown strong efficacy in mid-stage trials in China [5] Amgen - Amgen currently does not have an approved weight loss medicine but is progressing with its leading candidate, MariTide, which is in phase 3 studies [6] - MariTide is being investigated for weight management, obstructive sleep apnea treatment, and cardiovascular outcomes, and could potentially earn approval within the next three years [8] - Amgen's market cap is $199 billion, with a current price of $369.47 and a gross margin of 70.47% [7][8] - MariTide's once-a-month administration could provide a competitive advantage over Wegovy, which is taken weekly, and it is estimated to generate $3.7 billion in sales by 2030 [8] Comparative Analysis - Novo Nordisk has a stronger portfolio and pipeline of weight loss products but is heavily reliant on its GLP-1 products for growth, facing market share losses to competitors like Eli Lilly [9] - Amgen has a more diversified portfolio, which may allow it to recover quickly even if it does not succeed in the weight-loss market [10] - While Novo Nordisk has more upside potential if its pipeline drugs succeed, its prospects are closely tied to the performance of its anti-obesity drugs, making it riskier [11] - Amgen is viewed as a safer investment option for exposure to the weight-loss market with limited downside risk [11]

整理 | GLP1减重宝典内容团队 2026年3月，对于全球制药界来说，注定是一个历史性的时刻。备受关注的减肥神药——司美格鲁肽，其核心化合物的专利在中国正式到期， 这标志着它将迎来一场市场格局的巨大变革。 根据中国国家知识产权局的登记信息，诺和诺德的司美格鲁肽核心化合物专利（专利号：200680006674.6）将于2026年3月20日到期。尽管诺 和诺德在2025年底成功赢得了为期四年半的专利保卫战，但这场胜利为诺和诺德带来的喘息期仅有不到90天。 四年专利战，终究挡不住时间到 价格"跳水"时代即将来临 预计，一旦多款国产司美格鲁肽获得批准，市场价格将迅速下跌。业内专家表示，减重药物的价格很可能进入"白菜价"时代。诺和诺德已经嗅 到了寒意，为应对国产仿制药的压力，诺和诺德在2025年底主动将司美格鲁肽注射液价格下调近50%，这一举措不仅是应对国产药物的"提前防 御"，也是应对替尔泊肽的竞争。 替尔泊肽（GLP-1/GIP双靶点）作为诺和诺德的直接竞争对手，于2025年成功纳入中国国家医保目录，并在2026年1月开始享受医保报销。与 此同时，电商平台上替尔泊肽的促销价格更是低至2折，这对诺和诺德来说，无疑加 ...

Core Viewpoint - The long-standing dispute between Novo Nordisk and Hims & Hers Health is reportedly coming to an end, with both companies set to announce a new partnership allowing Novo to sell its weight-loss drug Wegovy through Hims' platform [1][2]. Group 1: Partnership Details - Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health's platform, marking a significant shift in their relationship [2]. - The two companies had a previous agreement that was terminated by Novo after Hims continued to market copycat medications [2]. Group 2: Market Reaction - Following the news of the partnership, Novo's ADRs rose by 2% in after-hours trading, while Hims' shares surged nearly 40% [4]. - The end of the feud is viewed positively for Hims' stock, as noted by Leerink Partners analyst Michael Cherny [3]. Group 3: Strategic Rationale - Novo's decision to partner with Hims again is likely driven by the need to expand market reach and improve performance amid a competitive obesity treatment landscape [6][9]. - The new CEO of Novo is under pressure from investors to reverse a multi-year stock decline, which may have influenced the decision to collaborate with Hims [9]. Group 4: Analyst Insights - Analysts have noted that the rationale for the partnership's announcement may be explained by executives from either company, potentially addressing the poor year-to-date performance of both firms [7]. - Goldman analyst James Quigley recently downgraded Novo's stock from "Buy" to "Hold," indicating a cautious outlook despite the new partnership [10].

Core Viewpoint - Hims & Hers Health stock experienced a significant after-hours surge of 39% following the resolution of a legal dispute with Novo Nordisk, shifting investor sentiment positively towards the company [1][4][7]. Company Developments - The stock closed the regular trading session at $15.74, down approximately 0.88%, due to ongoing regulatory concerns and market caution [1]. - The after-hours trading saw the stock rise to $22, indicating a strong market reaction to the news [1]. - The legal conflict with Novo Nordisk revolved around Hims & Hers offering compounded alternatives to Novo's branded obesity drugs, which had led to lawsuits and regulatory scrutiny [4]. Partnership Impact - The new partnership allows Novo Nordisk to provide its FDA-approved weight-loss medications directly through the Hims & Hers platform, effectively ending the previous legal disputes [5]. - This collaboration is expected to create new revenue opportunities for Hims & Hers and alleviate the regulatory pressures that had negatively impacted the stock [7]. - The partnership is viewed as a significant positive shift, enhancing long-term growth prospects in the obesity treatment market [7]. Market Reaction - The announcement of the partnership sparked enthusiasm among both retail and institutional investors, leading to a surge in after-hours trading volume [8]. - Shares of Novo Nordisk also saw a modest increase, reflecting the perceived mutual benefits of the partnership [8]. - The rapid repricing of Hims & Hers stock highlights its sensitivity to developments in the weight-loss market [9].

Core Insights - Hims & Hers Health (HIMS) stock surged 40% in aftermarket trading after a partnership with Novo Nordisk, which had previously sued Hims over GLP-1 drugs, signaling a recovery in revenue streams [1] - The partnership allows Hims to sell Novo's branded obesity medications, including Wegovy and Ozempic, directly through its platform, ending a legal dispute and restoring investor confidence [1] Company Overview - Hims & Hers initially gained popularity during the telehealth boom, expanding from hair-loss treatments to a significant player in the weight-loss market with GLP-1 agonists [1] - The company faced a severe downturn, with stock prices dropping 77% from their peak due to regulatory pressures and a failed partnership with Novo Nordisk [1] Industry Dynamics - Novo Nordisk's partnership with Hims is a strategic move to regain market share lost to Eli Lilly's Zepbound, which has been performing well in terms of efficacy and marketing [1] - The collaboration allows Novo to leverage Hims' telehealth platform for broader distribution without the need to build its own infrastructure, while Hims benefits from a high-margin product line that is crucial for customer acquisition [1] Risks and Challenges - Hims remains dependent on Novo for its growth driver, which poses risks if regulatory conditions change or if Novo decides to alter distribution strategies [1] - Despite diversifying into other health areas, Hims' future growth is still heavily reliant on the success of GLP-1 medications, making it vulnerable to market fluctuations [1]

Core Insights - Novo Nordisk is facing increasing competition in the weight loss drug market, particularly from Eli Lilly's Zepbound, which has outperformed Novo's CagriSema in clinical trials [1][9] - The company has announced promising results from a phase 2 study of UBT251, a new weight loss candidate that targets multiple gut hormones, potentially enhancing its efficacy [4][9] Clinical Trial Results - In a study conducted in China, UBT251 demonstrated a mean weight loss of up to 19.7% over 24 weeks, indicating strong potential [5] - CagriSema achieved an average weight loss of 23% over 84 weeks, while Zepbound led to a 25.5% weight loss in the same timeframe, highlighting the competitive landscape [5][9] - UBT251's phase 2 results suggest it could outperform both Zepbound and CagriSema in studies of similar duration [6] Market Position and Future Outlook - Novo Nordisk's market cap stands at $130 billion, with a gross margin of 80.90% and a dividend yield of 4.48%, indicating financial stability [8] - Despite challenges, the weight loss market is projected to exceed $100 billion in sales over the next decade, providing a potential recovery path for Novo Nordisk [10] - The company is expected to maintain its position as the second-leading drugmaker in the weight loss sector, with UBT251 and other candidates in development [9]

Core Insights - Novo Nordisk A/S is set to sell its weight-loss drugs on Hims & Hers Health Inc.'s platform, marking the end of a legal dispute between the two companies [1][3] - A new partnership announcement is expected soon, following a previous agreement that was terminated by Novo due to Hims marketing copycat medications [2][3] - The partnership is seen as a positive development for Hims, with its shares surging 40% in after-hours trading, while Novo's American depositary receipts rose 2.1% [3][4] Company Developments - Novo Nordisk had previously sued Hims for launching a copycat version of its Wegovy weight-loss pill, accusing Hims of breaching US patents [3] - The partnership indicates that Novo is under pressure to regain market share in the competitive obesity market, where it has been losing ground to competitors like Eli Lilly & Co. [5] - Novo's strategy includes expanding partnerships with telehealth companies to enhance market reach, as seen with its collaborations with Ro and Weight Watchers [6] Industry Context - The telehealth sector has seen companies like Hims capitalize on the opportunity to sell lower-cost alternatives during supply shortages of weight-loss drugs [6] - The FDA has recently indicated plans to address the rise of copycat weight-loss drugs, which may impact the market dynamics [7]

Core Viewpoint - The article discusses the 12 best undervalued stocks to invest in currently, highlighting insights from Katie Stockton regarding market trends and specific stock recommendations [1][4]. Market Trends - The S&P 500 has been range-bound, with support around 6750, and a neutral short-term bias has been maintained [1][2]. - Momentum has deteriorated across all time frames, raising concerns about market entry amid increased volatility, as indicated by the VIX breaking out to the upside [2]. Stock Recommendations - **TotalEnergies SE (NYSE:TTE)**: Price targets raised by Berenberg to EUR 62 and Citi to EUR 75, with a Buy rating due to strong valuation support amid geopolitical tensions [9][10]. - **The Toronto-Dominion Bank (NYSE:TD)**: Reported earnings of $4.0 billion, up 45% year-over-year, with price targets raised by Scotiabank to C$142 and CIBC to C$140 [12][13]. - **Royal Bank of Canada (NYSE:RY)**: Reported record net income of $5.8 billion, up 13% year-over-year, with price targets adjusted by Scotiabank to C$247 and TD Securities to C$259 [15][16]. - **Rio Tinto Group (NYSE:RIO)**: Announced a joint venture for a desalination plant to deliver 8GL of water annually, reducing pressure on regional aquifers [18][20]. - **Shell plc (NYSE:SHEL)**: Price targets raised by JPMorgan to 3,600 GBp and Citi to 2,950 GBp, with strong operational performance reported in Q4 2025 [22][23]. - **Novo Nordisk A/S (NYSE:NVO)**: Upgraded to Equal Weight with a price target adjustment to $40, following FDA approval for new indications of a growth hormone [25][26]. - **Newmont Corporation (NYSE:NEM)**: Price target raised to $150 by Citi, with a bullish outlook on gold and reported mineral reserves of 118.2 million ounces [29][30].

Novo Nordisk (NYSE:NVO) is one of the stocks that should double in 3 years. On February 4, Novo Nordisk delivered 10% sales growth in 2025, driven by its obesity and diabetes portfolios. The company’s obesity care sales reached DKK 82 billion, marking a substantial increase since 2019 and expanding its reach to 16 million additional patients. Financial results surpassed expectations with a reported EPS of $1, although the gross margin decreased to 81% due to manufacturing acquisitions and restructuring cos ...

从临床证据看，诺和诺德用COMBINE 1、2、3三项III期研究来支撑它的降糖定位与对照优势。COMBINE 1把IcoSema与依柯胰岛素对比，在 基线HbA1c约8.22%的前提下，IcoSema的HbA1c降幅更大，同时体重从下降到上升形成明显分叉，呈现出复方在代谢层面的综合收益。 COMBINE 2则把它与司美格鲁肽1.0mg对比，同样在HbA1c改善上占优，但体重结果显示，复方为了更强的降糖与更偏胰岛素化的作用组合， 体重管理幅度不如单用司美格鲁肽那样突出，这也提示它更像是给需要更强降糖覆盖的人群准备的方案，而不是以减重为核心的那条线。 COMBINE 3把它放到更复杂的基础加餐时胰岛素方案面前，结果显示降糖效果不落下风，而体重端更有优势，强化了它在简化方案与减轻体重 负担之间的定位。 这张牌为什么此时落地，关键看中国2型糖尿病治疗的真实场景。很多患者从口服药走到需要加用基础胰岛素的阶段，最常见的焦虑是两件事： 一是打针复杂、依从性差，二是体重上升带来的长期风险和心理负担。传统基础胰岛素强化降糖的同时，体重往往容易走高；GLP-1在体重与 代谢上更友好，但对部分患者而言单药不够，或后续仍要叠加胰岛 ...